You are here: Industry Insights > TNBC

News List

Everest Medicines Announces Taiwan, China,China FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer prnasia
January 04, 2022
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia...
Gilead and Merck collaborate for breast cancer combination treatment Pharmaceutical-Technology
November 01, 2021
Gilead Sciences and Merck (MSD) have signed a clinical trial partnership and supply agreement to assess the efficacy of the former’s Trodelvy (sacituzumab govitecan-hziy) along with...
EC approves Merck’s Keytruda and chemotherapy combination for TNBC patients Pharmaceutical-Business-Review
October 28, 2021
The European Commission (EC) has approved Merck’s Keytruda (pembrolizumab) plus chemotherapy combination to treat triple-negative breast cancer (TNBC) patients.
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China prnasia
July 29, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa (also known as ...
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan, China FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer prnasia
July 29, 2021
Everest Medicines announced today that the Taiwan, China Food and Drug Administration (FDA) has granted Pediatric and Rare Severe Disease Priority Review Designation for sacituzumab govitecan-hziy (SG).
FDA Approves Breast Cancer Treatment americanpharmaceuticalreview
July 29, 2021
The FDA approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 21, 2021
Everest Medicines announced that sacituzumab govitecan-hziy (SG) was granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 17, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the China National Medical Products Administration (NMPA) ...
AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC pharmatimes
May 11, 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ACD) datopotamab deruxtecan has demonstrated 'promising' preliminary response and disease control in new data evaluating the therapy among patients with metastatic triple negative breast ...
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 06, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea ...

Previous page 1 2 3 Next page